Secondary analysis of dried blood spots from infants with congenital CMV on valganciclovir 16 mg/kg twice daily (ValEAR RCT or an open-label PK study): ganciclovir triphosphate had a half-life of about 21 days, with an expected ~62-fold rise from first dose to steady state.
Secondary analysis
Lindquist-Kleissler et al. Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection